Nephrologists Are Reluctant to Accept Janssen’s INVOKANA
Millions of Americans suffer from Type 2 diabetes, and about one-quarter of those patients have kidney disease, which makes the diabetic kidney disease one of the biggest reasons for morbidity in the USA.
INVOKANA was approved in 2019 as the first sodium-glucose cotransporter 2 (SGLT2) inhibitor. It should reduce the risk of terminal kidney disease, cardiovascular death, worsening of kidney function, and hospitalization for heart failure in adults with type 2 diabetes and DKD (nephropathy) who have a certain amount of protein in the urine.
More than one-third of nephrologists fear to prescribe SGLT2 inhibitors for their DKD patients. Most are not comfortable and state they lack education and information about the drug and would not initiate the therapy themselves.
The COVID-19 crisis affected all areas of life, so 95% of the surveyed nephrologists stated they had no interaction with an INVOKANA sales representative in the past month.
Nephrologists are taking baby steps on the full embracement of INVOKANA as a treatment for their DKD patients.
But, they are optimistic about the potential for this class to improve outcomes.
Invokana helps patients with type 2 diabetes to regulate blood sugar levels. It helps the kidneys in discharging blood in the body, by blocking SGLT2 carriers that normally reabsorb and release glucose back into the bloodstream.
Like any medication, INVOKANA also has side effects such as nausea, vomiting, difficulty focusing, fatigue, burning during urination, bloody urine, fever.
After the drug’s approval, the FDA asked Johnson & Johnson to follow conflicting cardiovascular events connected with the drug.
Invokana can cause a lot of serious complications and side effects, but most lawsuits are related to ketoacidosis, stating that there was no warning about side effects and dangers of DKA.
Contact hurt.com if you have any issues after using this drug.
Pfizer Inc Files Petition Against Indian Company Aurobindo Pharma Ltd Over Cancer Drug Ibrance
Are Manual Transmissions Making a Comeback?